Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Background. Contrast-induced acute kidney injury (CI-AKI) is a leading cause of hospital-acquired kidney injury, particularly in patients exposed to contrast media during diagnostic procedures. While several risk stratification tools exist, the Mehran Risk Scoring System remains the most widely used and validated model for predicting CI-AKI in cardiac-related interventions.
Objectives. This study aimed to determine the accuracy of Mehran Risk Scoring (MRS) for contrast induced nephropathy in patients who underwent Non-Cardiac Related Contrast Media Studies. Specifically, it sought to describe the respondents’ clinical and demographic characteristics and also aimed to determine the period prevalence of CI-AKI post CECT, compute the Mehran risk scores for these patients, and evaluate the scoring system’s predictive accuracy in terms of sensitivity and specificity.
Methods. This study utilized a retrospective cohort design, wherein data from admitted patients who underwent non-cardiac contrast-enhanced imaging procedures over a 10-year period were reviewed and analyzed. Eligible patients included primarily adults with no prior diagnosis of AKI, and who had both baseline and follow-up serum creatinine measurements. Descriptive statistics were used to summarize the characteristics of the participants. The discriminatory ability of the Mehran Scoring system to predict AKI was evaluated using a Receiver Operating Characteristic (ROC) curve. Diagnostic metrics were computed to assess the performance of the scoring system in detecting AKI.
Results. Across 526 contrast-enhanced CT examinations, CI-AKI occurred in 6.8%, with early peaks around 13% (2015-2016) dropping to 2.9% by 2024. Patients were evenly split by sex, typically middle-aged (median 56 years), and largely preserved renal function (median eGFR ≈ 99). Hypertension and diabetes were common, while severe heart failure, hypotension, and hypoalbuminemia were less frequent but concentrated in higher Mehran risk strata. Most cases (78%) were low-risk per Mehran Score; no patients reached “very-high” risk. A cutoff of ≥5.5 yielded excellent diagnostic performance (sensitivity 97%, specificity 83%, AUC 0.94). , establishing the score’s utility—particularly as a powerful rule-out tool for CI-AKI.
Conclusion. Based on these results, the MRS system demonstrated excellent predictive accuracy for CI-AKI in patients undergoing non-cardiac contrast-enhance CT at our hospital. With high sensitivity and specificity, and an AUC of 0.94, the scoring system proved to be a valuable diagnostic tool, particularly effective in ruling out CI-AKI at a threshold of <5.5. This affirms the potential utility of Mehran Scoring beyond cardiac procedures and supports its application in broader clinical settings to enhance patient safety and risk stratification.
